Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
04
2020
accepted:
01
06
2020
entrez:
14
7
2020
pubmed:
14
7
2020
medline:
14
7
2020
Statut:
epublish
Résumé
Oxaliplatin and irinotecan are generally used to treat advanced colorectal cancer (CRC) patients. Antibiotics improve the cytotoxicity of oxaliplatin but not irinotecan in a colon cancer cell line In oxaliplatin groups 1 and 2, the response rate (RR) was 58.2% and 30.2%, while the disease control rate (DCR) was 92.5% and 64.2%, respectively; the median progression-free survival (PFS) was 10.5 months (95% confidence interval (CI) = 7.5-12.2) and 7.0 months (95% CI = 17.0-26.0), respectively, and the median overall survival (OS) was 23.8 months (95% CI = 5.1-9.1) and 17.4 months (95% CI = 13.1-24.9), respectively. In irinotecan groups 1 and 2, the RR was 17.8% and 20.0%, while the DCR was 75.6% and 69.1%, respectively; the median PFS was 8.2 months (95% CI = 6.2-12.7) and 7.9 months (95% CI = 12.0-23.0), respectively, and the median OS was 16.8 months (95% CI = 5.9-10.6) and 13.1 months (95% CI = 10.4-23.7), respectively. To improve the treatment efficacy of oxaliplatin-based therapy in advanced CRC patients, adding antibiotics is a potential therapeutic option.
Sections du résumé
BACKGROUND
BACKGROUND
Oxaliplatin and irinotecan are generally used to treat advanced colorectal cancer (CRC) patients. Antibiotics improve the cytotoxicity of oxaliplatin but not irinotecan in a colon cancer cell line
RESULTS
RESULTS
In oxaliplatin groups 1 and 2, the response rate (RR) was 58.2% and 30.2%, while the disease control rate (DCR) was 92.5% and 64.2%, respectively; the median progression-free survival (PFS) was 10.5 months (95% confidence interval (CI) = 7.5-12.2) and 7.0 months (95% CI = 17.0-26.0), respectively, and the median overall survival (OS) was 23.8 months (95% CI = 5.1-9.1) and 17.4 months (95% CI = 13.1-24.9), respectively. In irinotecan groups 1 and 2, the RR was 17.8% and 20.0%, while the DCR was 75.6% and 69.1%, respectively; the median PFS was 8.2 months (95% CI = 6.2-12.7) and 7.9 months (95% CI = 12.0-23.0), respectively, and the median OS was 16.8 months (95% CI = 5.9-10.6) and 13.1 months (95% CI = 10.4-23.7), respectively.
CONCLUSION
CONCLUSIONS
To improve the treatment efficacy of oxaliplatin-based therapy in advanced CRC patients, adding antibiotics is a potential therapeutic option.
Identifiants
pubmed: 32655636
doi: 10.1155/2020/1701326
pmc: PMC7317329
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1701326Informations de copyright
Copyright © 2020 Hiroo Imai et al.
Déclaration de conflit d'intérêts
Chikashi Ishioka, the corresponding author, received research funding from the Tokyo Cooperative Oncology Group, received contributions from Chugai Pharmaceutical, Ono Pharmaceutical, MSD, Pfizer, AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical, and is a representative of Tohoku Clinical Oncology Research and Education Society, a specified nonprofit corporation. Masanobu Takahashi received research funding from Ono Pharmaceutical.
Références
Ann Intern Med. 2019 Mar 19;170(6):389-397
pubmed: 30856657
Genome Res. 2012 Feb;22(2):299-306
pubmed: 22009989
Cancer Res Treat. 2017 Jul;49(3):816-823
pubmed: 27857024
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Jpn J Clin Oncol. 1993 Aug;23(4):250-7
pubmed: 8411739
Lancet Oncol. 2010 Sep;11(9):853-60
pubmed: 20708966
Lancet Oncol. 2013 Dec;14(13):1278-86
pubmed: 24225157
Gynecol Oncol. 2006 Feb;100(2):412-6
pubmed: 16298422
Cancer Manag Res. 2019 Aug 22;11:7953-7965
pubmed: 31686910
N Engl J Med. 2002 Jan 10;346(2):85-91
pubmed: 11784874
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Cancer Res. 2014 Mar 1;74(5):1311-8
pubmed: 24385213
Lancet Oncol. 2012 Nov;13(11):1125-32
pubmed: 23062232
Genome Res. 2012 Feb;22(2):292-8
pubmed: 22009990
Nat Rev Drug Discov. 2008 Feb;7(2):123-9
pubmed: 18239669
Science. 2017 Sep 15;357(6356):1156-1160
pubmed: 28912244
J Clin Oncol. 2008 Jul 20;26(21):3523-9
pubmed: 18640933
Eur J Clin Pharmacol. 2015 May;71(5):589-601
pubmed: 25795200
Int J Colorectal Dis. 2009 Sep;24(9):1097-109
pubmed: 19495779
J Clin Oncol. 2012 May 1;30(13):1513-8
pubmed: 22412140
Ann Oncol. 2000 Nov;11(11):1477-83
pubmed: 11142489
Ann Oncol. 2015 Jan;26(1):141-148
pubmed: 25316259